Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Synaffix
Synaffix
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
Innovent Biologics and Synaffix expand ADC collaboration
New deal builds on encouraging preliminary clinical data from the Phase I study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021
Drug Delivery
Lonza to acquire Synaffix and strengthen ADCs offering
The companies will continue to expand their "Centre of Excellence" for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies
Regulatory
Synaffix expands licensing agreement with MacroGenics
The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion
Distribution
Synaffix announces licensing agreement with CKD Pharm
Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments
Drug Delivery
Synaffix enters ADCs agreement with Amgen
Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments
Digital
Synaffix wins ‘Best ADC Platform Technology’ at World ADC Awards
This marks the second time that Synaffix’s ADC platform technology has been acknowledged as industry leading
Research & Development
Synaffix strikes ADC deal with MacroGenics
Under the agreement, Synaffix will be eligible to receive up to $586m in payments
Subscribe now